These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 18243718

  • 1. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 2. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y, Pinedo IR, Tapuria N, Zabron A, Davidson BR.
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 4. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 5. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D.
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [Abstract] [Full Text] [Related]

  • 6. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y, Tapuria N, Kirmani N, Davidson BR.
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [Abstract] [Full Text] [Related]

  • 7. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
    Lüftner D, Mazurek S, Henschke P, Mesterharm J, Schildhauer S, Geppert R, Wernecke KD, Possinger K.
    Anticancer Res; 2003 Mar; 23(2A):991-7. PubMed ID: 12820337
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Mar; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 10. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S, Seiffert UB.
    Anticancer Res; 1997 Mar; 17(4B):3031-3. PubMed ID: 9329593
    [Abstract] [Full Text] [Related]

  • 11. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
    Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M.
    Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
    [Abstract] [Full Text] [Related]

  • 12. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
    Zhong LP, Zhu HG, Zhang CP, Chen WT, Zhang ZY.
    Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
    [Abstract] [Full Text] [Related]

  • 13. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E.
    Cancer Detect Prev; 2000 Mar; 24(6):531-5. PubMed ID: 11198266
    [Abstract] [Full Text] [Related]

  • 14. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999 Mar; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 15. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999 Mar; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 16. Pyruvate kinase type tumor M2 in urological malignancies.
    Hegele A, Varga Z, Kosche B, Stief T, Heidenreich A, Hofmann R.
    Urol Int; 2003 Mar; 70(1):55-8. PubMed ID: 12566817
    [Abstract] [Full Text] [Related]

  • 17. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003 Mar; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 18. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
    Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D.
    Int J Cancer; 2005 Dec 10; 117(5):825-30. PubMed ID: 15957165
    [Abstract] [Full Text] [Related]

  • 19. Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients.
    Zhong LP, Zhang CP, Zheng JW, Li J, Chen WT, Zhang ZY.
    Arch Oral Biol; 2007 Nov 10; 52(11):1079-87. PubMed ID: 17612501
    [Abstract] [Full Text] [Related]

  • 20. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure.
    McDowell G, Gupta S, Dellerba M, Coppinger T, Levy RD, Keevil BG.
    Ann Clin Biochem; 2004 Nov 10; 41(Pt 6):491-3. PubMed ID: 15588442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.